Sarcoidosis is an inflammatory granulomatous disorder affecting mostly the lungs. Spontaneous remission often occurs, although around one third of patients have chronic disease, which can be fatal. 1, 2 The cause of sarcoidosis is not yet fully understood, but immunologic evidence and its geographic variation have suggested causes, including infection, occupational exposure, and genetic factors. The presence of clonal T H 1-like CD4 1 T cells, macrophages, and immune effector cells within affected organs suggests an antigen-driven autoimmune disease. 3 Autoantigens, such as vimentin and ATP synthase, have been identified as targets for expanded T-cell clones in the lung, 4 and other data suggest roles of microorganisms because of the T-cell reactivity against mycobacterium tuberculosis catalase-peroxidase (mKatG). 5 Exosomes are 30-to 150-nm vesicles derived from endosomal compartments, which act as messengers between cells 6 and can either stimulate or inhibit immune cells, depending on their cellular origin. 7 Dendritic cell exosomes can stimulate T cells 8, 9 and are promising cancer vaccine candidates, 10, 11 but exosomes from the gut and cancer cells seem to inhibit the immune system. 12, 13 Exosomes have been found in most body fluids, including breast milk 14 and plasma, 15 and are likely to play physiologic roles and have potential as disease biomarkers.
We have previously found exosomes in bronchoalveolar lavage fluid (BALF) of healthy subjects 16 and shown in functional studies that BALF from patients with sarcoidosis is enriched in proinflammatory exosomes and can induce production of IFN-g and IL-8 in vitro. 17 In further functional studies we have shown that macrophage-and dendritic cell-derived exosomes carry leukotriene (LT) pathway components and have migration-inducing capacities, suggesting that exosomes might contribute to airway remodeling. We have also established that BALF exosomes in asthmatic patients carry LT-forming enzymes and functionally induce production of cytokines and LTs. 19 Recently, it was also found that exosomes promote the chemotaxis of neutrophils by transporting LTB 4 . 20 Taken together, the accumulating evidence points to a role of exosomes in LT-mediated intercellular communication, possibly with implications in patients with airway disease.
In view of the latter evidence, we aimed to thoroughly dissect disease-associated components of BALF exosomes from patients with sarcoidosis. We conducted a full proteomic analysis of the exosomal contents, followed by validations of the most interesting results using flow cytometry, ELISA, Western blotting, and nanoparticle tracking analysis (NTA). We detected clear proteomic differences between exosomes from patients with sarcoidosis and control subjects, with proinflammatory and immune system activation pathway components more abundant in patients' exosomes. Several of the proteomic findings, including an increase in LT-forming enzymes, were successfully validated by using several techniques, as were a number of potential biomarkers. These findings indicate the importance of future investigations of the role of these proteins in exosomes in patients with sarcoidosis but also as disease biomarkers to support the invasive and circumstantial diagnostic procedures of patients with sarcoidosis.
METHODS

Study subjects
BALF from 44 patients with sarcoidosis (median age, 46 years; 52% male and 11% smokers), 3 patients with fibrosis, 2 asthmatic patients, and 1 patient with alveolitis was obtained as part of routine diagnostic investigations at Karolinska Hospital, Sweden. Sarcoidosis diagnoses were established according to World Association of Sarcoidosis and Other Granulomatous Disorders guidelines 21 based on typical clinical signs, biopsy specimens showing noncaseating granuloma formation, and chest radiographic findings compatible with sarcoidosis. The diagnoses were further supported by differential BALF cell counts and BALF CD4/CD8 ratios and by ruling out other causes of these observations. Patients with L€ ofgren syndrome (n 5 9) were identified based on acute onset of the disease with fever, erythema nodosum, and/or ankle arthritis and bilateral hilar lymphomas with or without concomitant parenchymal infiltrates. None of the patients had received any kind of immunosuppressant therapy at the time of bronchoscopy. Healthy control subjects (n 5 22; median age, 27 years; 68% male and 14% smokers) free of medication with normal chest radiographs, blood cell counts, and electrolytes volunteered for bronchoalveolar lavage (BAL). No participants had signs of respiratory tract infection at least 4 weeks before the bronchoscopy. All the subjects had normocalcemia at the time of bronchoscopy, which is reported together with the other characteristics of the patients, including smoking habits, x-ray stages, and serum calcium and angiotensin-converting enzyme levels, where available (see Table E1 in this article's Online Repository at www.jacionline.com). All subjects provided informed consent adhering to protocols approved by the regional ethics committee.
Exosome isolation from BALF and blood
BAL was performed, as described previously. 22 BALF was strained through a double layer of Dacron nets (Millipore, Bedford, Ireland) and centrifuged at 400g for 10 minutes at 48C. Cell viability was determined by mean of Trypan blue exclusion and was always greater than 90%. BALF exosomes were isolated by means of differential centrifugation, as described elsewhere. 17 Plasma exosomes were isolated by centrifuging whole blood at 600g for 10 minutes, and the supernatant was further centrifuged at 20,000g for 20 minutes. This supernatant was filtered through a 0.22-mm filter and ultracentrifuged at 140,000g for 90 minutes, after which, the pellet was washed in PBS.
Sample preparation and isobaric tags for relative and absolute quantification labeling Isobaric tags for relative and absolute quantification (iTRAQ) reagents and buffers were obtained from AB Sciex (Framingham, Mass). Additional reagents, including triethyl ammonium bicarbonate, liquid chromatographymass spectrometry grade acetonitrile, and methyl methanethiosulfonate, were obtained from Sigma (St Louis, Mo). Sequence-grade trypsin was used for protein digestion (Promega, Madison, Wis). All aqueous solutions were prepared by using water from a Milli-Q water purification system (Merck Millipore, Billerica, Mass). BALF exosomes were prepared for proteomic analysis, as previously described, 14 with modifications to accommodate for labeling with 8-plex iTRAQ reagents (AB Sciex), as described in the Methods section in this article's Online Repository at www.jacionline.com.
Liquid chromatography-tandem mass spectrometry
An Orbitrap Velos coupled to an Easyn-LC (Thermo Scientific, Waltham, Mass) was used for liquid chromatography-tandem mass spectrometry (LC-MS/MS). Additional analyses were made with the QSTAR Elite (AB Sciex), together with an UltiMate 3000 capillary LC (Dionex, Sunnyvale, Calif). The data were directly analyzed with ProteinPilot software and the Paragon identification algorithm with a human Swiss-Prot database (release August, 18, 2011; 20,245 entries).
Flow cytometry
To characterize the exosomes based on original BALF volume, 4.5-mm anti-human HLA-DR beads (clone HKB-1; Dynal, Oslo, Norway) were coated with BALF exosomes corresponding to 6 mL of the original BALF volume per microliter of beads and stained with fluorescein isothiocyanate (FITC)-conjugated antibodies to HLA-DR, HLA-ABC, CD9, CD54, CD63, CD81, CD86, dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) (BD Biosciences, San Diego, Calif), or Mucin 1, cell surface associated (MUC-1) (Abcam, Cambridge, Mass), as previously described. 17 For validation of the iTRAQ results, where exosomal quantities were based on total protein contents, 2 mg of BALF exosomes was added per microliter of 4-mm latex beads (Molecular Probes, Paisley, United Kingdom) coated with anti-human CD63 (BD Biosciences) and stained with HLA-DR-FITC, CD63-phycoerythrin, CD55-FITC (BD Biosciences), or C3-phycoerythrin (LSBio LifeSpan Bioscience, Seattle, Wash) or with isotype-matched controls. Samples were analyzed with a BD Biosciences FACSCalibur and FlowJo software (TreeStar, San Carlos, Calif).
Western blotting for LT pathway proteins and complement C3
Methods for Western blotting for detection of LTs and complement C3 are found in the Methods section in this article's Online Repository.
ELISA for VDBP
Thirteen healthy control subjects and 6 patients with nonsarcoidosis lung disorders (3 with fibrosis, 2 with asthma, and 1 with alveolitis) were analyzed by using an ELISA kit, according to the manufacturer's protocols (R&D Systems, Minneapolis, Minn), to quantify exosome-associated VDBP, BALF exosomes from 14 patients. Both plasma and exosomes isolated from the plasma of 23 patients and 11 healthy control subjects were analyzed in the same manner.
Sucrose gradient separation of exosomes
Because VDBP has not been reported previously to be associated with exosomes, we confirmed this by analyzing VDBP in exosome fractions isolated by using sucrose gradient centrifugation. BALF exosomes from 5 patients with sarcoidosis were pooled and separated on a continuous sucrose gradient (0.25-2 mmol/L sucrose and 20 mmol/L HEPES/NaOH, pH 7.4; Sigma-Aldrich, St Louis, Mo) by means of centrifugation for 20 hours at 17,900g at 48C. Fraction densities were determined by using refraction index measurements. Each fraction was ultracentrifuged at 100,000g for 35 minutes to pellet the exosomes for detection of VDBP by means of ELISA, as described above.
NTA
NTA was used to relate the quantities of exosomes between patients and healthy subjects. For a detailed description of the methods used in this study, see the Methods section in this article's Online Repository.
Bioinformatics and statistical analyses
The Reproducibility-Optimised Test Statistic 23 was initially used to analyze the iTRAQ-determined protein abundances between healthy subjects and patients with sarcoidosis. To identify differences between groups, either the nonparametric Mann-Whitney test or Kruskal-Wallis test was performed with GraphPad Prism 5 software (GraphPad Software, La Jolla, Calif). A P value of less than .05 was considered significant. More details are found in the Methods section in this article's Online Repository.
RESULTS
Isolation and characterization of exosomes from BALF
In agreement with our previous findings, 17 BALF from patients with sarcoidosis showed total exosomal protein amounts greater than 2 times higher than those in BALF from healthy control subjects (P < .0001, data not shown). Smoking status did not significantly affect exosome protein amounts. BALF cell phenotypes in patients are displayed in this article's Online Repository at www.jacionline.org.
Phenotype of exosomes analyzed in iTRAQ
Exosomes from the 15 patients and 5 control subjects included in the iTRAQ analysis were coated to anti-MHC class II beads and analyzed by using flow cytometry. These analyses detected CD63 and CD9 exosome markers (Fig 1, A and B) , as well as HLA-ABC (see Fig E1, B, in this article's Online Repository at www.jacionline.org), on exosomes of both patients and healthy control subjects. Patients' exosomes displayed significantly higher expression of HLA-DR (P 5 .0012) and CD54 Open circles indicate patients with L€ ofgren syndrome, and solid circles represent patients with chronic sarcoidosis. **P < .01, Mann-Whitney or Kruskal-Wallis test (the latter for patients with L€ ofgren syndrome/patients with non-L€ ofgren disorders/healthy subjects).
(P 5 .0052; Fig 1, C and D) compared with those of healthy control subjects. This difference remained significant also when the patients with L€ ofgren syndrome were excluded from statistical analysis.
Identification of proteins in BALF exosomes by using iTRAQ
The proteomic profiles of exosomes from 15 patients and 5 healthy control subjects were analyzed by using LC-MS/MS after labeling with iTRAQ reagents. On average, 1,400 proteins and 16,000 peptides were detected in each of the 3 iTRAQ experiments performed, with overall detection of 1,479 proteins with 2 or more distinct peptides at an estimated false discovery rate of 5% (see the Methods section in this article's Online Repository). Although 840 proteins were detected in exosome samples from all subjects (>1 peptide; http://www. microvesicles.org 24 ), we focused on a shorter list of 690 proteins for the statistical analysis, which was filtered to limit the influence of quantification measurements based on single values (see the Methods section in this article's Online Repository).
The DAVID bioinformatics tool was used to gain insight into the biological processes associated with the major changes in protein abundance. Enrichment and clustering analysis were made for the Gene Ontology biological processes associated with the proteins altered more than 2-fold between the patients and healthy control subjects. The complete list of Gene Ontology biological processes are listed (see the Methods section in this article's Online Repository) and summarized in Fig 2. Also, the list of proteins altered 2-fold or more between patients and healthy control subjects are displayed in Table E2 , A and B, in this article's Online Repository at www.jacionline.com.
A large number of proteins were more abundant in patients' exosomes, including glycoproteins involved in cell-cell interaction, LPS-binding protein, and VDBP. Levels of kininogen-1, lactotransferrin, prothrombin, serotransferrin, haptoglobulin, and apolipoprotein B-100 were also increased in the patients. Furthermore, patients' exosomes had a higher abundance of proteins involved in homeostasis and hemostasis, as well as inflammation, including membrane attack complex (MAC) proteins and enzymes involved in LT metabolism. The 4 IgG subclasses and proteins related to activation of adaptive immunity were upregulated in patients. Hierarchical clustering of the iTRAQ results also highlighted the increase in complement system activators (Fig 3) , including C3, in patients compared with control subjects (P 5 .0012). However, the abundance of complement decay-accelerating factor (CD55), a complement system inhibitor, was higher in the healthy control subjects (P 5.0045; Fig 4, A) . Among the proteins that were less abundant in patients' exosomes were components from metabolic processes, such as ubiquitination and proteasome activation.
Validation of iTRAQ results
For the proteins highlighted in the iTRAQ analysis, a number of the most promising biomarker candidates and functionally interesting proteins were verified by using other techniques. These targets included complement-related proteins, components of the LT pathway, and vitamin D-binding protein (VDBP).
Complement-related proteins. Flow cytometric analysis of C3 and CD55 on BALF exosomes from 12 patients and 9 healthy control subjects showed that the lower levels of CD55 seen by using iTRAQ (Fig 4, A) could be verified (P 5 .0016; Fig 4, B) . Complement component C3, however, which was found by using iTRAQ to be more abundant in patients (Fig 5, A) , showed no difference (P 5 .456; Fig 5, B) . However, because flow cytometric analysis detects only epitopes exposed on exosomal surfaces, Western blotting was used to investigate total C3 levels. Western blot analysis showed that C3 was clearly present in patients' exosomes but barely detectable in healthy control subjects (Fig 5, C) .
Proteins of the LT pathway
Leukotriene A 4 hydrolase (LTA 4 H) is a potent chemoattractant for several types of leukocytes and the enzyme that converts LTA 4 to LTB 4 . The iTRAQ data indicated that LTA 4 H was more abundant in patients' exosomes (Fig 6, A) , and Western blot analysis clearly verified this (Fig 6, B) , showing a significantly higher band intensity in BALF exosomes from patients with sarcoidosis compared with those from healthy subjects (P 5 .02; Fig 6, C) . On the other hand, 5-lipoxygenase (5-LO), which catalyzes formation of LTA 4 from arachidonic acid, was found to be 1.3-fold more abundant in BALF exosomes of healthy subjects by using iTRAQ (see the Methods section in this article's Online Repository), which was validated with Western blot analysis (P 5 .024; Fig 6, B) .
In keeping with our earlier findings, 18 we demonstrated a more stable fluorescent signal in 5-LO-activating protein exosomes compared with b-actin, suggesting 5-LO-activating protein to be a more suitable reference protein for BALF exosomes.
VDBP
Vitamin D dysregulation has been described in patients with sarcoidosis, and here we present the first evidence associating exosomes with this topic. The iTRAQ analysis indicated a 2-fold upregulation of VDBP (see Table E2 , A) in BALF exosomes from patients with sarcoidosis compared with those from healthy subjects (P 5 .0012; Fig 7, A) . To validate these differences, we analyzed BALF exosomes from 14 patients with sarcoidosis, 13 control subjects, and 6 patients with other lung diseases (3 with fibrosis, 2 with asthma, and 1 with alveolitis) by means of ELISA. We found significantly higher levels of VDBP in exosomes from patients with sarcoidosis compared with those from both healthy control subjects (Fig 7, B) and patients with lung disorders other than sarcoidosis (data not shown). To further evaluate VDBP as a disease biomarker, we used an ELISA to analyze VDBP in plasma from 23 patients and 11 control subjects but found slightly lower levels of VDBP in patients (Fig 7, C) . However, when investigating exosomes isolated from the plasma, a significantly higher VDBP level was seen in the patients (Fig 7, D) , suggesting that disease-associated levels of VDBP are more distinct in exosomes compared with those in whole plasma. This difference remained significant when the patients with L€ ofgren syndrome were excluded from the statistical analysis.
Receiver operating characteristic analysis of the plasma exosome-associated levels of VDBP produced an area under curve of 0.83 (95% CI, 0.69-0.97; P 5 .0024). On the basis of CD55 levels are lower in BALF exosomes from patients than in those from healthy control subjects, as measured by using iTRAQ and flow cytometry. A, Relative abundance of CD55 compared with a pooled reference, as measured by using iTRAQ in patients with sarcoidosis and healthy control subjects. B, CD55 levels on exosomes bound to anti-CD63-coated beads and measured by using flow cytometry adjusted to isotype-matched control. Open circles indicate patients with L€ ofgren syndrome, and solid circles indicate patients with chronic sarcoidosis. **P < .01, Mann-Whitney or Kruskal-Wallis test (the latter for patients with L€ ofgren syndrome/patients with non-L€ ofgren disorders/healthy subjects).
these data, if the exosomal VDBP concentration were used as a diagnostic test, a threshold concentration of 24.4 ng/mL (based on the Youden index of the receiver operating characteristic curve) could be used to discriminate patients from healthy subjects with a sensitivity of 73.9% and a specificity of 81.2%, with positive and negative predictive values of 89% and 60%, respectively (see Fig E5 in this article's Online Repository at www.jacionline.com). However, further measurements from a wider cohort of cases and control subjects would be needed to robustly validate VDBP as a clinically applicable biomarker for sarcoidosis. We also verified that VDBP is not simply copelleted with exosomes during centrifugation by detecting VDBP in the sucrose gradient fraction corresponding to the exosomal density (see Fig E2, A, in this article's Online Repository at www.jacionline.com). Plasma exosome quantities were also compared between patients and healthy control subjects by using NTA, which showed no significant difference in vesicle concentrations between the groups (see Fig E2, B) . Plasma exosome levels of VDBP were also plotted against disease stage and the main C   62  64  40  33  18  43  21  38  45  100  75   H1  H2  H3  H4  H5  P1  P2  P3  P4  P5 A, Relative abundance of C3 compared with an internal pooled reference measured by using iTRAQ in patients with sarcoidosis and healthy control subjects. B, C3 levels on exosomes bound to CD63-coated beads and measured by using flow cytometry adjusted to isotype-matched controls. C, Western Blot analysis of C3 in protein isolates from BALF exosomes of patients with sarcoidosis (P1-P6) and healthy control subjects (H1-H5). Before transfer, the gel was scanned for total protein contents; relative intensities correlating with protein amounts are plotted in percentage of the strongest sample. MW, Molecular weight marker. Open circles indicate patients with L€ ofgren syndrome, and solid circles indicate patients with chronic sarcoidosis. **P < .01, Mann-Whitney or Kruskal-Wallis test (the latter for patients with L€ ofgren syndrome/patients with non-L€ ofgren disorders/healthy subjects). 
DISCUSSION
We have previously demonstrated in functional studies that BALF exosomes from patients with sarcoidosis induce proinflammatory effects in PBMCs and epithelial cells 17 and that BALF exosomes of asthmatic patients induce the production of IL-8 and LTs when added to epithelial cells. 19 We conducted the current study to investigate possible mechanisms behind this proinflammatory role of exosomes in airway disease. We compared the proteome of BALF exosomes between patients with sarcoidosis and healthy subjects by using iTRAQ to screen for targets for further investigation. The most interesting results were verified by means of flow cytometry, ELISA, and Western blotting. For the first time, these novel data demonstrate that VDBP is present on BALF exosomes and its expression is significantly increased in patients with sarcoidosis compared with healthy control subjects. A higher VDBP level was also found in exosomes isolated from the plasma of patients with sarcoidosis (23 patients vs 11 healthy control subjects), strengthening the possibility of using exosome-bound VDBP as a biomarker. We also show that exosomes from patients with sarcoidosis carry LT-forming enzymes, which is in keeping with our and others' observations of exosome involvement in LT pathways. [17] [18] [19] [20] Levels of complement factors and proteins involved in inflammatory processes were also increased in patients, as were levels of proteins involved in innate and adaptive immune responses, protein maturation, hemostasis, and homeostasis, which supports a proinflammatory role for exosomes in patients with sarcoidosis and might explain their cytokine-inducing capacity, which we previously reported. 17 Previous studies have shown proteome profiles of total BALF of patients with lung disorders, [25] [26] [27] [28] including sarcoidosis, 29 but not BALF exosomes. In 2002, Magi et al 25 demonstrated that the protein composition of BALF in patients with sarcoidosis has a more inflammatory protein profile, including calgranulin A and B, cyclophilin A, complement activator components, and VDBP, when compared with patients with idiopathic pulmonary fibrosis. In addition, Sabounchi-Sch€ utt et al 26 reported that BALF samples from patients with sarcoidosis had higher levels of proteins involved in immune responses and in inflammatory processes compared with those from healthy control subjects. However, in our study, which to our knowledge is the first full proteomic analysis with validations of exosome proteins in BALF, the data suggest that exosomes might be more specific markers compared with the whole proteome. Complement activators, such as complement factors B, C1q, C1s, C1r, C2, and C3 and MAC, showed higher relative abundance in patients, whereas levels of the complement inhibitors CD55 and CD59 were decreased. This might reflect a protective role of exosomes, which clear complement activators from cells in inflamed areas through removal of MAC, possibly to protect surrounding cells from MAC attack. 30, 31 On the other hand, C3 fragment-containing exosomes might potentiate antigenspecific immune responses. 32 Taken together, the presence of complement activators and the low expression of inhibitors of the complement system suggest that BALF exosomes in patients with sarcoidosis might play a modulatory role in the disease.
The iTRAQ data indicated that C3 levels were more than 2-fold higher in patients compared with those in healthy control subjects. Flow cytometry of the exosomes did not show the same trend, possibly because of localization of C3 in exosomes inaccessible to flow cytometric antibodies. Indeed, Western blot analyses for C3 showed that although C3 was clearly present in BALF exosomes from patients, it was barely detectable in healthy control subjects, confirming the iTRAQ findings. This could be interpreted as meaning that C3 is only accessible to recipient cells after internalization of exosomes. Intracellular C3 has been shown to sustain T-cell homeostasis and mediate effector differentiation 33 and therefore might drive T-cell activation and IFN-g production in these patients. Localization inside exosomes also suggests that C3 is loaded in exosomes during formation and not bound to them after production and release.
LTs are inflammatory mediators produced by oxidation of arachidonic acid through an enzymatic cascade initiated by 5-LO, mediating the epoxide formation by LTA 4 synthase activity. 34 The final product, LTA 4 , can be converted by LTA 4 H to the proinflammatory LTB 4 . 35 Earlier studies have reported the presence of soluble LTA 4 H in human BALF with LTB 4 -producing capacities, 36 and we have detected LTA 4 H in BALF exosomes from patients with allergic asthma, whereas 5-LO levels were almost undetectable. 19 In the present study both the iTRAQ results and Western blot analyses showed that LTA 4 H was significantly more abundant in BALF exosomes from patients with sarcoidosis, whereas 5-LO was more abundant in control subjects. This apparently inverted pattern in patients compared with healthy subjects suggests an altered LT pattern in those with sarcoidosis and warrants further investigation, especially given the amplitude of already available LT-modifying drugs that are possibly beneficial for patients with sarcoidosis. Our previous findings of IL-8 induction by LT enzymes in asthma exosomes and the observation of high levels of exosomes in patients with sarcoidosis (as shown in this study) 17 suggests that these enzymes associated with exosomes might be conveying inflammatory signals also in patients with sarcoidosis.
Granulomas in patients with sarcoidosis express high levels of 1a-hydroxylase, an enzyme that catalyzes hydroxylation of 25-OH vitamin D to its active form, 1,25(OH)2 vitamin D, 37 which has been found to be positively associated with sarcoidosis. 38 VBDP is the primary transporter of vitamin D and makes it available to specific tissues and cell types. 39 VDBP bound to complement component 5a also has a chemotactic effect on neutrophils and macrophages, 40, 41 and VDBP can act as a macrophage-activating factor. 42 VDBP has been previously detected in BALF from patients with sarcoidosis 26, 29 and plasma, 43 although not in connection with exosomes and not with any increase in plasma. We found VDBP at 2-fold (by iTRAQ) higher levels in BALF exosomes of patients with sarcoidosis compared with those of healthy subjects and successfully validated these findings by using ELISA and showed that VDBP was not increased in any of the subjects in a control group of patients with nonsarcoidosis lung disorders (3 with fibrosis, 2 with asthma, and 1 with alveolitis). Diagnosing sarcoidosis is a circumstantial task, and better diagnostic procedures are warranted. To evaluate exosome-associated VDBP as a biomarker in blood, we investigated exosomes isolated from plasma of patients with sarcoidosis and found significantly higher levels of VDBP compared with those seen in healthy control subjects. The higher levels of VDBP in plasma exosomes of patients with sarcoidosis are not attributed to increased numbers of exosomes, as shown by using NTA, but rather to enrichment for the protein in the exosomes. The fact that only exosome-associated but not total VDBP levels were increased in patients further supports the use of exosomes as biomarkers, and if we are able to select organ-specific exosomes (ie, from the lung) for analysis, we might increase specificity and sensitivity even further.
In conclusion, the observed differences in exosome protein expression between patients with sarcoidosis and healthy control subjects suggest a role for exosomes in several central inflammatory systems, including LT pathways. These findings might help clarify the progress or driving cause of sarcoidosis and A, Relative abundance of VDBP on BALF exosomes, as detected by using iTRAQ relative to a pooled reference. B, VDBP on BALF exosomes from healthy control subjects and patients with sarcoidosis, as measured by using ELISA. In the sarcoidosis group open circles indicate patients with L€ ofgren syndrome, and solid circles indicate patients with chronic disease. C, VDBP measured in plasma of patients and healthy control subjects by using ELISA. D, VDBP levels on exosomes isolated from plasma, as measured by using ELISA. *P < .05 and **P < .01, Mann-Whitney or Kruskal-Wallis test (the latter for patients with L€ ofgren syndrome/patients with non-L€ ofgren disorders/healthy subjects).
provide new directions for its prophylaxis or treatment. We also highlight exosome-associated complement components and VDBP as candidates for sarcoidosis biomarkers. Diagnosing sarcoidosis is a complex task, and our finding that exosomes can carry disease biomarkers even in patients' plasma, opens up possibilities for both improved diagnostic studies and future studies on the implications of exosomes in patients with sarcoidosis.
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Clinical implications: Sarcoidosis is associated with invasive diagnostic procedures, and exosomes represent potential new diagnostic and prognostic biomarkers. These data also contribute to our understanding of the inflammatory properties of exosomes.
